Exai Bio
PrivateLast Round
Grant
Sep 19, 2024
Est. Valuation
$130.6M
Total Funding Raised
$140.74M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Exai Bio operates in Healthcare & Life Sciences and is based in Palo Alto, California. Its latest recorded funding round was a Grant round in September 2024.
Exai Bio is a biotechnology company that develops a liquid biopsy platform utilizing oncRNA technology and artificial intelligence for early cancer detection and personalized treatment guidance.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exai Bio Comparables
Compare Exai Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Precede Biosciences | 86% | |
| Flomics Biotech | 83% | |
| Hummingbird Diagnostics GmbH | 83% |
For institutional investors. Book with your work email.
Exai Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 19, 2024 | ||||
| Grant | Sep 25, 2023 | ||||
| Series A Extension | Oct 1, 2022 | ||||
| Series A | Dec 9, 2021 | ||||
| Grant | Apr 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Exai Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series A, Series A Extension |
| National Cancer Institute | Grant |
| NIH RADx | Grant |
| Blue Cross Blue Shield Association | Series A |
| Moore Strategic Ventures | Series A Extension |
| Two Sigma Ventures | Series A, Series A Extension |
| Casdin Capital | Series A, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 51% MoM, reaching 5.8K.
- Oct 1, 2022
$71M round led by S32 and Casdin Capital.
For institutional investors. Book with your work email.
Exai Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Exai Bio's valuation, stock price, and market status.
Is Exai Bio a public or private company?
Exai Bio is a private company.
What is the current stock price of Exai Bio?
Exai Bio is a private company, so its shares have no public market price. Caplight tracks Exai Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Exai Bio worth (valuation)?
Exai Bio's valuation is estimated at $130.6M based on funding round data.
Can I buy Exai Bio stock?
Exai Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Exai Bio's last funding round?
Exai Bio's most recent funding round was Grant on September 19, 2024.
Who are the main investors in Exai Bio?
Key investors in Exai Bio include S32, Casdin Capital.
Will Exai Bio IPO soon?
No public IPO plans have been announced for Exai Bio.
How can I track Exai Bio secondary market activity?
Caplight tracks bids, offers, and trades in Exai Bio's shares on secondary markets.